Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2022 May 5;8(3):E18-E19.
doi: 10.1093/ehjcvp/pvac009.

Thromboprophylaxis for COVID-19-related coagulopathy: what next?

Viktor Čulić  1   2 , Riccardo Vio  3 , Riccardo Proietti  4
Affiliations
Editorial

Thromboprophylaxis for COVID-19-related coagulopathy: what next?

Viktor Čulić et al. Eur Heart J Cardiovasc Pharmacother. .
No abstract available

PubMed Disclaimer

Comment in

Comment on

References

    1. Thachil J, Cushman M, Srivastava A. A proposal for staging COVID-19 coagulopathy. Res Pract Thromb Haemost 2020;4:731–736. - PMC - PubMed
    1. Hippensteel JA, LaRiviere WB, Colbert JF, Langouët-Astrié CJ, Schmidt EP. Heparin as a therapy for COVID-19: current evidence and future possibilities. Am J Physiol Lung Cell Mol Physiol 2020;319:L211–L217. - PMC - PubMed
    1. Ortega-Paz L, Galli M, Capodanno D, Franchi F, Rollini F, Bikdeli B, Mehran R, Montalescot G, Gibson CM, Lopes RD, Andreotti F, Angiolillo DJ. Safety and efficacy of different prophylactic anticoagulation dosing regimens in critically and non-critically ill patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials. Eur Heart J Cardiovasc Pharmacother; doi.org/10.1093/ehjcvp/pvab070. Published online ahead of print 14 September 2021. - PMC - PubMed
    1. Spyropoulos AC, Goldin M, Giannis D, Diab W, Wang J, Khanijo S, Mignatti A, Gianos E, Cohen M, Sharifova G, Lund JM, Tafur A, Lewis PA, Cohoon KP, Rahman H, Sison CP, Lesser ML, Ochani K, Agrawal N, Hsia J, Anderson VE, Bonaca M, Halperin JL, Weitz JI, HEP-COVID Investigators . Efficacy and safety of therapeutic-dose heparin vs. standard prophylactic or intermediate-dose heparins for thromboprophylaxis in high-risk hospitalized patients with COVID-19: the HEP-COVID randomized clinical trial. JAMA Intern Med 2021;181:1612–1620. - PMC - PubMed
    1. The ATTACC, ACTIV-4a, and REMAP-CAP Investigators . Therapeutic anticoagulation with heparin in noncritically ill patients with Covid-19. N Engl J Med 2021;385:790–802. - PMC - PubMed

MeSH terms